scholarly journals THE FUNCTIONAL STATUS OF THE SKIN BARRIER IN CHILDREN WITH ATOPIC DERMATITIS

2013 ◽  
Vol 10 (1) ◽  
pp. 52-57
Author(s):  
E T Kindeeva ◽  
E E Varlamov ◽  
A N Pampura
Keyword(s):  
Staphylococcus Aureus ◽  
Atopic Dermatitis ◽  
Topical Therapy ◽  
Skin Barrier ◽  
Specific Ige ◽  
Transepidermal Water Loss ◽  
Severe Atopic Dermatitis ◽  
Skin Ph ◽  
Skin Colonization

Introduction. One of the factors in the pathogenesis of atopic dermatitis is a dysfunction of the skin barrier. Background. To reveal the features of the barrier function of the skin in children with atopic dermatitis by measuring transepidermal water loss (TEWL) and the pH of the skin. Methods. The study included 98 children with atopic dermatitis. All patients measurement was performed by TEWL (Tewameter TM 300, Multi Probe Adapter MPA 5/9, Courage + Khazaka) and the pH of the skin (Skin-pHMeter, Multi Probe Adapter MPA 5/9, Courage + Khazaka). Results. TEWL value was significantly higher in children with severe atopic dermatitis (p=0,00001), in children up to 3 years (p=0,002), in patients with skin colonization of Staphylococcus aureus (p=0,006) and with specific IgE to staphylococcal enterotoxins. Skin pH was significantly higher in children with severe atopic dermatitis (p=0,0001), and in children under the age of 3 years (p=0,04). Conclusion. The determination of the level of TEWL and skin pH to assess the degree of inflammation activity in atopic dermatitis and to justify use of topical therapy, aimed to restoring the epidermal barrier of the skin at children with atopic dermatitis, is substantiated.

scholarly journals CLINICAL SIGNIFICANCE OF DETERMINATION OF IGE ANTIBODIES TO STAPHYLOCOCCUS AUREUS AND MALASSEZIA SPECIES IN SERUM OF CHILDREN WITH ATOPIC DERMATITIS

2018 ◽  
Vol 63 (4) ◽  
pp. 84-88
Author(s):  
T. S. Okuneva ◽  
M. V. Kushnareva ◽  
A. N. Pampura ◽  
E. E. Varlamov ◽  
N. G. Konyukova
Keyword(s):  
Staphylococcus Aureus ◽  
Atopic Dermatitis ◽  
Clinical Significance ◽  
Specific Ige ◽  
Frequency Of Occurrence ◽  
Ige Antibodies ◽  
Malassezia Species ◽  
Specific Ige Antibodies ◽  
Malassezia Spp

We studied the frequency of occurrence and concentration of allergen-specific IgE antibodies (asIgE) to enterotoxins A, B, C and TSST-1 of Staphylococcus aureus and Malassezia spp. in the serum of children with atopic dermatitis in the acute period of the disease. The determination of asIgE levels was performed in 84 children aged from 5 months to 17 years using the immunochemiluminescent method on the UniCAP 100 analyzer (Phadia, Sweden). The level of asIgE was evaluated on a scale of 6 classes.The sensitization to S. aureus enterotoxins was detected in 29 children with аsIgE concentration from 0.35 to 25.8 kU/L (I–IV classes). In 16 children were observed 8 polysensitization options to S. aureus allergens. Combinations of asIgE to A + B and A + B + C enterotoxins were most common – in every fourth and fifth child,respectively. Sensitization to Malassezia spp. was observed in 41 children with concentration from 0.38 to 98.9 KU/L (I–V classes). Polysensitization to both S. aureus and Malassezia spp. allergens was observed in one of two children. A higher degree of sensitisation to Malassezia spp allergens has been established compared to S. aureus.Conclusion. To improve the specific diagnostics of atopic dermatitis, it is advisable to examine the serum for a complete panel of recombinant S. aureus enterotoxins in combination with the determination of asIgE to Malassezia spp. 

scholarly journals Chamaejasmine Isolated from Wikstroemia dolichantha Diels Suppresses 2,4-Dinitrofluoro-benzene-Induced Atopic Dermatitis in SKH-1 Hairless Mice

Biomolecules ◽  
2019 ◽  
Vol 9 (11) ◽  
pp. 697 ◽  
Author(s):  
Tae-Young Kim ◽  
No-June Park ◽  
Jonghwan Jegal ◽  
Sangho Choi ◽  
Sang Woo Lee ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Clinical Symptoms ◽  
Skin Barrier ◽  
Topical Administration ◽  
Skin Lesions ◽  
Specific Ige ◽  
Transepidermal Water Loss ◽  
Skin Barrier Function ◽  
Enzyme Linked Immunosorbent Assay ◽  
Dermal Thickness

Plants of the genus Wikstroemia have long been used as traditional medicines to treat diseases like pneumonia, rheumatism, and bronchitis. This study was designed to determine the effect of chamaejasmine, a biflavonoid present in W. dolichantha, on atopic dermatitis (AD)-like skin lesions in a 2,4-dinitrochlorobenzene (DNCB)-induced murine model of AD. Initially, we examined the anti-allergic activities of ten flavonoids from W. dolichantha by measuring β-hexosaminidase release from RBL-2H3 cells. Subsequently, an SKH-1 hairless mouse model of AD was developed based on the topical application of DNCB. Chamaejasmine (0.5%) or pimecrolimus (1%, positive control) were applied to dorsal skins of DNCB-sensitized AD mice for two weeks. Serum IL-4 and IgE levels were determined using enzyme-linked immunosorbent assay kits and transepidermal water loss (TEWL) and skin hydration were measured using a Tewameter TM210 and a SKIN-O-MAT, respectively. Of the ten flavonoids isolated from W. dolichantha, chamaejasmine most potently inhibited DNP-specific IgE-induced degranulation in RBL-2H3 cells. Topical administration of chamaejasmine attenuated the clinical symptoms of DNCB-induced dermatitis (i.e., itching, dryness, erythema, and edema). Histological analyses demonstrated that dermal thickness and mast cell infiltration in dermis were significantly reduced by chamaejasmine. In addition, 0.5% chamaejasmine inhibited DNCB-induced increases in total IL-4 and IgE levels in serum, improved skin barrier function, and increased epidermis moisture. Our findings suggest chamaejasmine might be an effective therapeutic agent for the treatment of atopic diseases.

scholarly journals Experience of combined topical therapy with methylprednisoloni aceponatis and «Bepanten Plus»® in treatment of adult patients with moderate and severe atopic dermatitis

2015 ◽  
Vol 12 (6) ◽  
pp. 80-83
Author(s):  
O K Shtyrbul ◽  
O A Erina ◽  
E S Fedenko
Keyword(s):  
Staphylococcus Aureus ◽  
Atopic Dermatitis ◽  
Combined Therapy ◽  
Topical Therapy ◽  
Adult Patients ◽  
Severe Atopic Dermatitis ◽  
Bacterial Isolation ◽  
Treatment Results ◽  
Lesional Skin ◽  
Days Of Therapy

Background. To estimate efficiency of combined therapy with methylprednisolone aceponatis and «Bepanten Plus»® in adult patients with moderate and severe atopic dermatitis. Methods. We examined 32 adult patients, who were treated with TGCS methylprednisolone aceponatis and «Bepanten Plus»®. The efficiency of therapy was estimated with index SCORAD, IGA and subjective patients assessment. For 15 of 32 patients swabs for bacterial isolation to estimate Staphylococcus aureus growth were taken from lesional skin before therapy and on the 14 th or 20 th days of treatment. Results. The аverage value of index SCORAD decreased after 15 days of therapy, Me 41,7 to Me 23,3 a point (p

scholarly journals Skin barrier status during dupilumab treatment in patients with severe atopic dermatitis

2021 ◽  
Vol 12 ◽  
pp. 204062232110583
Author(s):  
Silvia Ferrucci ◽  
Maurizio Romagnuolo ◽  
Carlo Alberto Maronese ◽  
Francesca Germiniasi ◽  
Simona Tavecchio ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Skin Barrier ◽  
Transepidermal Water Loss ◽  
Response To Therapy ◽  
Interleukin 4 ◽  
Severe Atopic Dermatitis ◽  
Barrier Dysfunction ◽  
Relative Variation ◽  
Good Tool ◽  
The Status

Background: Atopic dermatitis (AD) is a common chronic-relapsing inflammatory skin disease hallmarked by epidermal barrier dysfunction, increased transepidermal water loss (TEWL) and decreased skin hydration. Recent findings on the T helper 2 (Th2)-driven pathogenesis of AD have led to the development of dupilumab, a monoclonal antibody directed against interleukin-4 and interleukin-13 that has been demonstrated to be effective in the treatment of moderate-to-severe AD. The effect of dupilumab on skin barrier dysfunction, however, has not yet been adequately investigated. Objectives: The primary endpoint of this study was to assess the status of the skin barrier in nonlesional skin of patients with severe AD treated with dupilumab, by evaluating the association between the relative variation of TEWL and the achievement of a 75% reduction of EASI (EASI75) over time. Methods: TEWL was measured below the antecubital fossae by means of the Vapometer® at baseline, at week 4 (T4), at week 16 (T16) and at week 32 after dupilumab starting. EASI and NRS-itch were measured at the same time points. Results: Seventy-eight patients with severe AD treated with dupilumab were enrolled. Median TEWL relative variation respect to baseline was significantly higher in patients who achieved EASI75 as compared with those who did not achieve EASI75 at T16 and at T32, but not at T4. Conclusion: During dupilumab treatment, TEWL on nonlesional skin tends to significantly improve 4 months after treatment initiation and could be a good tool for monitoring response to therapy.

scholarly journals Skin Barrier Function in Psoriasis and Atopic Dermatitis: Transepidermal Water Loss and Temperature as Useful Tools to Assess Disease Severity

2021 ◽  
Vol 10 (2) ◽  
pp. 359 ◽  
Author(s):  
Trinidad Montero-Vilchez ◽  
María-Victoria Segura-Fernández-Nogueras ◽  
Isabel Pérez-Rodríguez ◽  
Miguel Soler-Gongora ◽  
Antonio Martinez-Lopez ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Disease Severity ◽  
Water Loss ◽  
Barrier Function ◽  
Skin Barrier ◽  
Transepidermal Water Loss ◽  
Diagnostic Tools ◽  
Psoriatic Skin ◽  
Skin Barrier Function ◽  
Healthy Controls

Multiple diagnostic tools are used to evaluate psoriasis and atopic dermatitis (AD) severity, but most of them are based on subjective components. Transepidermal water loss (TEWL) and temperature are skin barrier function parameters that can be objectively measured and could help clinicians to evaluate disease severity accurately. Thus, the aims of this study are: (1) to compare skin barrier function between healthy skin, psoriatic skin and AD skin; and (2) to assess if skin barrier function parameters could predict disease severity. A cross-sectional study was designed, and epidermal barrier function parameters were measured. The study included 314 participants: 157 healthy individuals, 92 psoriatic patients, and 65 atopic dermatitis patients. TEWL was significantly higher, while stratum corneum hydration (SCH) (8.71 vs. 38.43 vs. 44.39 Arbitrary Units (AU)) was lower at psoriatic plaques than at uninvolved psoriatic skin and healthy controls. Patients with both TEWL > 13.85 g·m−2h−1 and temperature > 30.85 °C presented a moderate/severe psoriasis (psoriasis area severity index (PASI) ≥ 7), with a specificity of 76.3%. TEWL (28.68 vs. 13.15 vs. 11.60 g·m−2 h−1) and temperature were significantly higher, while SCH (25.20 vs. 40.95 vs. 50.73 AU) was lower at AD eczematous lesions than uninvolved AD skin and healthy controls. Patients with a temperature > 31.75 °C presented a moderate/severe AD (SCORing Atopic Dermatitis (SCORAD) ≥ 37) with a sensitivity of 81.8%. In conclusion, temperature and TEWL values may help clinicians to determine disease severity and select patients who need intensive treatment.

scholarly journals Treatment of atopic dermatitis using non-thermal atmospheric plasma in an animal model

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Ik Jun Moon ◽  
Mi Ra Yun ◽  
Hae Kyeong Yoon ◽  
Keon Hee Lee ◽  
Sun Young Choi ◽  
...  
Keyword(s):  
Animal Model ◽  
Atopic Dermatitis ◽  
Skin Barrier ◽  
Treated Group ◽  
Transepidermal Water Loss ◽  
Atmospheric Plasma ◽  
Therapeutic Modality ◽  
Skin Barrier Function ◽  
Control Group ◽  
Epidermal Thickness

AbstractCold atmospheric plasma (CAP) has been incorporated into various fields, including promotion of cutaneous wound healing. Atopic dermatitis (AD) is a chronic cutaneous condition characterized by inflammation-induced skin wounds and impaired skin barrier function. To investigate whether CAP may improve AD using an animal model. Dermatophagoides farinae extracts (DFE)-induced murine models of AD were used in this study. The plasma-treated group received a total of 6 CAP treatments during 2 weeks, while the control group did not receive any treatment. Differences in dermatitis severity, transepidermal water loss (TEWL), serum level of immunoglobulin (Ig) E and epidermal thickness were evaluated in both groups. The dermatitis severity was significantly improved by CAP treatment. TEWL was lower in the plasma-treated group compared with the non-treated control group. Serum Ig E dropped significantly after treatment with CAP. Difference in epidermal thickness of the ear skin was not significant between the plasma-treated and non-treated groups. Localized treatment of AD with CAP decreases dermatitis severity, TEWL, and serum Ig E level. These results show CAP’s potentials as a novel therapeutic modality for AD.

Sign in / Sign up

Export Citation Format

Share Document